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Background: Cervical ectropion (also known as cervical erosion) is a common finding on routine pelvic examination
during the fertile years. The decision to treat or not remains controversial. According to studies in support of routine
treatment of cervical erosion, there is a possible relationship between squamous metaplasia and squamous cell
carcinoma of the cervix. To determine the prevalence of cervical ectropion and associated risk factors among clients
with intra-uterine contraceptive devices (IUCDs) attending a family planning clinic of a tertiary health institution in
Lagos, Nigeria.
Methods: A 5-year retrospective study was conducted by assessing existing clinic records from years 2007–2011.
Clients with IUCDs undergo routine pelvic examination during check-up visits. A total of 628 clients’ records were
seen within the stated time frame. This study was approved by the ethical committee of the Lagos State University
Teaching Hospital (LASUTH) and the collected data were analyzed using SPSS version 19.0.
Results: The mean age of the IUCD users was 34.7 ± 6.52 years, while 517 (82.3%) had secondary education.
On routine pelvic examination, seventy-nine clients (12.6%) had cervical ectropion. Thirty-nine (6.2%) clients had
presented with a history of abnormal vaginal bleeding while 12.1% had vaginal discharge. Treatments offered to
cases of cervical ectropion include cervical painting with gentian violet (89.9%) and antibiotics prescription (58.2%). On
bivariate analysis, previous hormonal contraceptive use (P = 0.041) and vaginal discharge (P < 0.001) were significantly
associated with developing cervical ectropion. Clients with ectropion were significantly more likely to receive
prescriptions for antibiotics (P < 0.001).
Conclusion: Less than one fifth of the clients had cervical erosion. However, routine pelvic examination could
aid the detection and control of latent reproductive health problems such as cervical ectropion which may require
further investigations for example, pap smears, to exclude potentially lethal conditions and to determine appropriate
treatment modality.
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Table 2 Socio-demographic characteristics of clients
Characteristic Frequency Percentage (%)
Age group (years)
15 - 20 4 0.6
21 - 25 32 5.1
26 - 30 144 22.9
31 - 35 188 29.9
36 - 40 143 22.8
>40 113 18.0












No data 14 2.2
Total 614 100.0
Age (Mean = 34.7 years, Median = 34 years, Mode = 35 years, Standard
Deviation = 6.52). The majority (75.6%) of respondents were between ages 26
and 40 years conforming averagely to the reproductive age range.
Table 1 Frequency distribution of clients by year of
registration at family planning clinic
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Cervical ectropion which is also called cervical ectopy
or erosion occurs when eversion of the endocervix ex-
poses columnar epithelium to the vaginal milieu [1]. The
prevalence of cervical ectropion ranges from 17% to 50%
[1-5]. A prevalence study in China among female users
of family planning services reported that 43.2% of the
women had cervical ectropion [6]. Another study on
women using oral contraceptive pills (OCPs) and IUCDs
in Benghazi, Libya also observed that cervical ectropion
was the commonest gynecological disorder among the
women (54.9%) [7]. Ectropion is considered to be a com-
mon physiological condition in adolescents and pregnant
women [1,8,9].
Cervical ectropion has been associated with both the
combined oral contraceptive pill and chlamydia tracho-
matis [1,8,10,11]. In a study among women attending a
sexually transmitted diseases clinic in USA, cervical ec-
tropion was positively associated with oral contraception
and Chlamydia trachomatis infection [8]. Inflammation
and trauma have also been implicated in the etiology of
cervical ectropion [8,12]. This is important considering the
fact that IUCD usage could be linked to inflammation and
trauma of the cervix. In view of the fact that vaginal dis-
charge is a common symptom of IUCD users, [9] changing
the method of contraception is a common practice for
women who are unable to accept the increase in physio-
logical discharge associated with cervical ectropion [13].
Reproductive tract infection is one of the major com-
plications caused by prolonged usage of IUCDs [14]. A
Turkish study showed that 14.7% of women using IUCDs
had cervical ectropion. Cervical ectropion and vaginal dis-
charge were also found to be significantly higher among
IUCD users compared with women on OCPs [15].
Furthermore, ectropion has been found in 5% to 25%
of women presenting with postcoital bleeding [16].
Differentiating between cervical ectropion and cervical
intraepithelial neoplasia macroscopically is difficult [17]. In
addition, available literature concerning treatment for cer-
vical ectropion can be described as controversial [12,13].
Some arguments advanced in support of routine treatment
include the relationship between squamous metaplasia and
induction of squamous cell carcinoma of the cervix [18].
Pre-cancerous lesions often develop at the squamous-
columnar junction, hence theoretically, treating cervical ec-
tropion may prove to be protective against the incidence of
cervical cancer [18]. Proponents of routine treatment have
also argued that some sexually transmitted microorganisms
such as Chlamydia trachomatis and Neisseria gonorrhea
preferentially infect glandular epithelium [10,15,19]. Thus
ectropion would, by exposing this epithelium, aid an in-
fective process [10,15,19]. Several treatment modalities
have been used for cases of ectropion including use of
antibiotics, microwave tissue coagulation, laser coagulation,infrared light, an interferon-alpha suppository, electro-
cautery or cryotherapy [2,12,13,20,21].
Based on the fore-going, the aim of this study was to
determine the prevalence of cervical ectropion and asso-
ciated risk factors among clients with IUCDs of a family
planning clinic in a tertiary health institution in Lagos
Nigeria.
Methods
A retrospective study was conducted by assessing exist-
ing clinic records between years 2007–2011. Clients
Table 3 Gynecological characteristics of clients
Characteristic Frequency Percentage (%)
Parity
Nulliparous 4 0.6
1 - 2 207 33.0
3 - 5 367 58.4
>5 38 6.1









No data 29 4.6
Total 628 100.0
History of hormonal contraceptives use
Yes 131 20.9
No 468 74.5
No data 29 4.6
Total 628 100.0
Parity (Mean = 3.19, Median = 3, Mode = 3, Standard Deviation = 1.51).
Table 5 Prevalence of cervical erosion among clients
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ing check-up visits. A total of 628 clients using IUCDs
were seen within the stated time frame. Clinical re-
cords of all 628 clients were assessed. Data from the
clinical records were collected using a register on the fol-
lowing information: socio-demographic and gynecological
characteristics of the clients, gynecological symptoms,
presence or absence of ectropion and the type of treat-
ment offered. The collected data were analyzed using
SPSS version 19.0 for windows. Descriptive statistics
were calculated for variables. Chi square test and mul-
tiple logistic regression tests were used to test forTable 4 Gynecological symptoms presented by clients








Total 628 100.0association between variables with level of signifi-
cance set at P < 0.05.
This study was approved by the ethical committee of the
Lagos State University Teaching Hospital (LASUTH).
Study limitations
1. Years 2009–2011 were characterized by periodic
industrial actions accounting for the drop in
clientele.
2. Furthermore, the obstetrics and gynecology clinics
within the hospital complex have been undergoing
structural renovation since year 2010 reducing the
capacity and services of the family planning clinic to
the bearest minimum in an improvised mini-clinic.
3. The study was retrospective; relying on records,
with no control over exposure or outcome. It was
also hospital-based and may not be readily
generalizable to the Nigerian population. However, it
provides useful information considering the paucity of
research works on cervical ectropion in Nigeria, in
addition to highlighting the need for future studies
using stronger study designs.
Results
The majority (88.2%) of the clients were seen between
2007 and 2008. (Table 1). The age of the IUCD users
ranged between 16 and 58 years with a mean of 34.7 ±
6.5 years, while 517 (82.3%) had secondary education, the
majority (81.4%) were Christians (Table 2).
The mean parity of clients using IUCD was 3.2 ± 1.5, with
a parity of 3–5 amongst 58.4% of the clients (Table 3). Four
hundred and one (65.3%) clients using IUCD had never used
any modern contraception previously while 131 (20.9%) had
used hormonal contraceptives in the past (Table 3). Most
(90.3%) clients had a 25–30 day menstrual cycle while 570
(90.8%) had their menstruation lasting for 3–5 days. Thirty-Table 6 Treatment received by clients with cervical
erosion (N = 79)
Treatment Yes No Chi square
No. (%) No. (%) P value
GV painting 71 (89.9) 8 (10.1) X2 = 28.3 df = 2
Antibiotics 46 (58.2) 33 (41.8) 95% CI = 0.02 to 5.99
GV paint with antibiotics 42 (53.2) 37 (46.8) P < 0.001
Table 7 Association between clients’ age and cervical erosion
Age group (Years) Cervical erosion Chi square P value
Yes frequency (%) No frequency (%) Total frequency (%)
15 - 20 0 (0.0) 4 (100.0) 4 (100)
21 - 25 5 (15.6) 27 (84.4) 32 (100) X2 = 5.44
26 - 30 15 (10.4) 129 (89.6) 144 (100) df = 5
31 - 35 18 (9.6) 170 (90.4) 188 (100) 95% CI = 0.554 to
36 - 40 21 (14.7) 122 (85.3) 143 (100) 11.07
>40 19 (16.8) 94 (83.2) 113 (100) P = 0.357
Total 78 (12.5) 546 (87.5) 624 (100)
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while 12.1% had vaginal discharge (Table 4).
Pelvic examination revealed that 79 (12.6%) clients had
cervical ectropion (Table 5).
Treatments offered to cases of cervical ectropion in-
clude cervical painting with gentian violet paint (89.9%)
and antibiotics (58.2%). Forty two clients who had cer-
vical ectropion received both cervical painting with gen-
tian violet and antibiotics (Table 6).
There was no statistically significant association between
age group of clients and presence of cervical erosion
(P>0.05, Table 7). On bivariate analysis, previous hormonal
contraceptive use (P = 0.041) and vaginal discharge (P <
0.001) were significantly associated with developing cervical
ectropion (Tables 8 and 9). Clients with ectropion were more
likely to receive prescriptions for antibiotics (P < 0.001).
Multiple logistic regression analysis was employed to
predict the probability that a client would have cervical ec-
tropion. The predictor variables were client’s age, parity,
history of previous use of hormonal contraceptives, pres-
ence of abnormal vaginal bleeding and presence of vaginal
discharge. A test of the full model versus a model with
intercept only was statistically significant, χ2 = 33.337,
d.f. = 5, p < 0.001.Table 8 Association between gynecological history and cervic
Gynecological history Cervical erosion
Yes frequency (%) No frequ
Parity
Nulliparous 1 (25.0) 3 (75.0)
1 - 2 16 (7.7) 191 (92.3
3 - 5 55 (15.0) 312 (85.0
>5 6 (15.8) 32 (84.2)
Total 78 (12.7) 538 (87.
Previous hormonal contraceptive
No 51 (10.9) 417 (89.1
Yes 23 (17.6) 108 (82.4
Total 74 (12.4) 525 (87.Table 10 shows the Multiple logistic regression coeffi-
cient, Wald test, odds ratio and 95% confidence interval
of odds ratio for each of the predictors. Employing a
P < 0.05 criterion of statistical significance, only presence
of vaginal discharge had a statistically significant partial ef-
fect on the presence of cervical ectropion. The odds ratio
for presence of vaginal discharge indicates that when hold-
ing all other variables constant, a client with vaginal dis-
charge is 2.56 times more likely to have cervical ectropion
than is a client without vaginal discharge. Although previ-
ous use of hormonal contraceptive was statistically signifi-
cantly associated with cervical ectropion on bivariate
analysis, this significant association was lost after multivari-
ate analysis.
Discussion
The prevalence of cervical ectropion among women
using IUCDs varies widely in the literature. In China the
prevalence in this group of women was 43.2% compared
to the 12.6% observed in this study [6]. The prevalence
was higher (26%) among IUCD users in a family planning
clinic at Edinburgh [1]. In a study to assess the effects of
IUCD and oral contraceptives on vaginal flora and epithe-
lium conducted in Turkey however, the prevalence ofal erosion
Chi square P value
ency (%) Total frequency (%)
4 (100) X2 = 7.23
) 207 (100) df = 3
) 367 (100) 95% CI = 0.115 to
38 (100) 7.81
3) 616 (100) P = 0. 065
) 468 (100) X2 = 4.19
) 131 (100) df = 1
6) 599 (100) 95% CI = 0.0 to 3.84 P = 0.041
Table 9 Association between gynecological symptoms and cervical erosion
Gynecological symptom Cervical erosion Chi square P value
Yes frequency (%) No frequency (%) Total frequency (%)
Abnormal bleeding
No 75 (12.7) 514 (87.3) 589 (100) X2 = 0.204
Yes 4 (10.3) 35 (89.7) 39 (100) df = 1
Total 79 (12.6) 549 (87.4) 628 (100) 95% CI = 0.0 to 3.84 P = 0. 806
Vaginal discharge
No 55 (10.0) 497 (90.0) 552 (100) X2 = 28 .38
Yes 24 (31.6) 52 (68.4) 76 (100) df = 1
Total 79 (12.6) 549 (87.4) 628 (100) 95% CI = 0.0 to 3.84 P <0.001
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to what has been observed in this study [15]. Notwith-
standing the fact that previous studies observed higher
prevalence of ectropion among IUCD users, the 12.6%
prevalence rate observed in this study indicates that
ectropion is a fairly common occurrence in this group
of women. A possible explanation for the occurrence of
cervical ectopy in IUCD users is the constant friction
between the hanging string and the cervical os.
This study observed that women were significantly more
likely to have developed an abnormal vaginal discharge if
they had cervical ectropion compared with those without
ectropion. A previous research has demonstrated an associ-
ation between use of the IUCD and cervical inflammation
and ectropion, either of which could potentially lead to ab-
normal discharge [4]. Vaginal samples for Trichomonas
vaginalis and other sexually transmitted diseases were not
obtained as part of this study. Therefore, it was not possible
to differentiate vaginal discharge due to pelvic infection
from that which may have been solely due to the ectropion.
However, it is known that prolonged use of IUCD is associ-
ated with increased risk of pelvic infection [15].
Studies have suggested that cervical ectropion is com-
mon among those taking estrogen-containing contra-
ceptives [1,11,22]. The observation from this study
that women who had a previous history of hormonal
contraceptive use were more likely to develop ectropion
(P < 0.05) however disappeared when other factors wereTable 10 Multiple logistic regression predicting cervical ectro
abnormal vaginal bleeding, and vaginal discharge
Predictor B Wald χ2
Age 0.025 1.185
Parity 0.112 1.214
Hormonal contraceptives use 0.525 3.229
Abnormal vaginal bleeding −0.583 0.851
Vaginal discharge 1.52 26.433
Omnibus Test of Model Coefficient (χ2 = 33.337, d.f. = 5, p < 0.001).taken into consideration (P = 0.072). This finding is sup-
ported by a study which observed that cervical ectropion
was more common among IUCD users than hormonal
contraceptive users [15]. This suggests therefore that pre-
vious use of hormonal contraceptives does not confer
additional risk of ectropion to IUCD users.
The tendency towards treating cervical ectropion is
strong as has been demonstrated in this study. Most of
the clients with ectropion in this study received some
form of treatment. Several treatment modalities are cur-
rently used in the clinical management of cervical ectro-
pion [13]. However the two modalities used in this study
comprise of the use of antibiotics and painting of the
cervix with gentian violet. The 12.6% prevalence of
ectropion means that a substantial number of women
were exposed to antibiotics. A contrary argument on the
current treatment modality is that inappropriate use of
antibiotics increases the risk of antimicrobial resistance
and places an unnecessary financial burden on patients
[23,24]. Moreover, in the context of cervical erosion be-
ing a non-infective and physiological condition, it may
resolve spontaneously without medical intervention.
Conclusions
The study findings indicate that cervical ectropion may
be a common occurrence among women using IUCD.
Reproductive health clinics offer screening opportunities
for various groups of women in the society. Therefore,pion from age, parity, hormonal contraceptives use,
p Odds ratio 95% CI for odds ratio
0.276 1.026 0.98 1.074
0.271 1.119 0.916 1.366
0.072 1.69 0.953 2.997
0.356 0.558 0.162 1.926
< 0.001 4.571 2.561 8.158
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http://www.biomedcentral.com/1756-0500/7/946routine pelvic examination should be emphasized for all
family planning clients as it could aid the detection and
control of latent reproductive health problems such as
cervical ectopy which may require further investigations
such as microscopy, culture and sensitivity as well as
pap smears to exclude potentially lethal conditions and
to determine appropriate treatment modality.
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